The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo …
…, AD Carides, J Ianus, ME Elmer, JK Evans… - Journal of clinical …, 2003 - ascopubs.org
Purpose: In early clinical trials with patients receiving highly emetogenic chemotherapy, the
neurokinin antagonist aprepitant significantly enhanced the efficacy of a standard antiemetic …
neurokinin antagonist aprepitant significantly enhanced the efficacy of a standard antiemetic …
Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomiting: Results …
…, G Julie Ma, K Eldridge, A Hipple, JK Evans… - Cancer, 2003 - Wiley Online Library
BACKGROUND Aprepitant is a novel neurokinin 1 (NK 1 ) antagonist that has been shown
to improve control of chemotherapy‐induced nausea and vomiting (CINV) when added to a …
to improve control of chemotherapy‐induced nausea and vomiting (CINV) when added to a …
A randomized trial of prenatal ultrasonographic screening: impact on the detection, management, and outcome of anomalous fetuses
JP Crane, ML LeFevre, RC Winborn, JK Evans… - American journal of …, 1994 - Elsevier
Objective: The objective of this randomized clinical trial was to test the hypothesis that
ultrasonographic screening would significantly alter perinatal outcome as a result of the antenatal …
ultrasonographic screening would significantly alter perinatal outcome as a result of the antenatal …
Effects of 6 months of moderate aerobic exercise training on immune function in the elderly
JA Woods, MA Ceddia, BW Wolters, JK Evans… - Mechanisms of ageing …, 1999 - Elsevier
The purpose of this study was to determine the effects of 6 months of moderate aerobic exercise
on age-dysregulated measures of T lymphocyte and natural killer (NK) cell number and …
on age-dysregulated measures of T lymphocyte and natural killer (NK) cell number and …
Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists
…, R Hargreaves, AD Carides, JK Evans… - European journal of …, 2003 - Elsevier
Advances in antiemetic therapy for chemotherapy-induced emesis have resulted in improved
protection against symptoms occurring within 24 h of chemotherapy. However, the vomiting …
protection against symptoms occurring within 24 h of chemotherapy. However, the vomiting …
Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy‐induced nausea and vomiting
…, A Taylor, AD Carides, JK Evans… - … Journal of the …, 2003 - Wiley Online Library
BACKGROUND The neurokinin‐1 antagonist aprepitant (EMEND™; Merck Research
Laboratories, West Point, PA) has been shown to reduce chemotherapy‐induced nausea and …
Laboratories, West Point, PA) has been shown to reduce chemotherapy‐induced nausea and …
Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy
JA Breyer, RP Bain, JK Evans, NS Nahman Jr… - Kidney International, 1996 - Elsevier
… ANDERSEN AR, CIIRISTIANSEN JS, ANDERSEN JK, KREINER S, DECKERT T: Diabetic
nephropathy in type I (insulin-dependent) diabetes: An epidemiological study. Diabetologia 25…
nephropathy in type I (insulin-dependent) diabetes: An epidemiological study. Diabetologia 25…
A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting
…, H Zhang, KJ Horgan, JK Evans… - Anesthesia & …, 2007 - journals.lww.com
BACKGROUND: Antiemetics currently in use are not totally effective. Neurokinin-1 receptor
antagonists are a new class of antiemetic that have shown promise for chemotherapy-…
antagonists are a new class of antiemetic that have shown promise for chemotherapy-…
The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events
OBJECTIVE: Etoricoxib is a selective cyclooxygenase inhibitor that in clinical studies has
improved the signs and symptoms of osteoarthritis and rheumatoid arthritis and reduced the …
improved the signs and symptoms of osteoarthritis and rheumatoid arthritis and reduced the …
Single-dose aprepitant vs ondansetron for the prevention of postoperative nausea and vomiting: a randomized, double-blind Phase III trial in patients undergoing …
…, AD Carides, T Reiss, JK Evans… - British journal of …, 2007 - academic.oup.com
Background The neurokinin 1 antagonist aprepitant is effective for prevention of
chemotherapy-induced nausea and vomiting. We compared aprepitant with ondansetron for …
chemotherapy-induced nausea and vomiting. We compared aprepitant with ondansetron for …